Stock of Australia based drug maker Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) have posted modest recovery during trading yesterday, after receiving a shellacking last week, when it share price was down by close to 77 percent. The sell off occurred after the drug maker reported that data from its ongoing clinical trial of drug candidate PBT2 designed to treat Alzheimer’s disease did not meet the preset end point goals of the clinical trial. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) shares after opening at $2.13 moved to $2.14 on last trade day and at the end of the day closed at $1.97. Company price to sales ratio in past twelve months was calculated as 280.53 and price to cash ratio as 4.81. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) showed a negative weekly performance of -18.60%.
On March 12,2014 Orexigen®Therapeutics, Inc. (Nasdaq:OREX), a biopharmaceutical company focused on the treatment of obesity, announced corporate and financial results for the fourth quarter and year ended December 31, 2013.The successful interim results of the Light Study give us confidence in the prospects for NB32 approvals in the U.S., Europe, and ultimately around the globe, and we believe the study creates value in addition to providing support for regulatory decisions,” said Michael Narachi, CEO of Orexigen. “The cardiovascular safety data make possible near-term lifecycle opportunities including the potential development of NB32 as a treatment for diabetes and in fixed dose combinations with other approved diabetes drugs. Additionally, we have filed new patent applications based on Light Study data which if issued would extend NB32 intellectual property protection to 2034.Orexigen Therapeutics, Inc. (NASDAQ:OREX) shares fell -7.36% in last trading session and ended the day on $5.54. OREX return on equity ratio is recorded as -179.80% and its return on assets is -64.50%. Orexigen Therapeutics, Inc. (NASDAQ:OREX) yearly performance is -8.43%.
Pernix Therapeutics Holdings (NYSE:PTX) major shareholder James Edward Jr. Smith unloaded 45,000 shares of Pernix Therapeutics Holdings stock on the open market in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $5.03, for a total value of $226,350.00. Following the completion of the sale, the insider now directly owns 4,567,704 shares in the company, valued at approximately $22,975,551. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) shares moved down -10.28% in last trading session and was closed at $4.89, while trading in range of $4.83-$5.44. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) year to date performance is 94.05%.
Depomed (NASDAQ:DEPO) had its price target upped by Roth Capital from $12.50 to $14.00 in a research note issued to investors on Friday, American Banking News.com reports. Depomed Inc (NASDAQ:DEPO) weekly performance is -3.40%. On last trading day company shares ended up $13.05. Depomed Inc (NASDAQ:DEPO) distance from 50-day simple moving average is -1.85%. Analysts mean target price for the company is $12.67.